Botox-maker Allergan's revenue drops 3 percent

(Reuters) - Allergan Plc <AGN.N> reported a 3 percent drop in quarterly revenue on Tuesday, as its faces increasing competition for its Alzheimer's treatment Namenda and other branded drugs.

The company posted net loss attributable to ordinary shareholders of $37.9 million (29.7 million pounds), or 11 cents per share, in the third quarter ended Sept. 30, compared with loss of $4.03 billion, or $12.07 per share, a year ago, which included a one-time charge.

Revenue fell 3 percent to $3.91 billion.

(Reporting by Manas Mishra in Bengaluru; Editing by Saumyadeb Chakrabarty)